Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Epistemonikos ID: 6052f7911a2302a6847ffd3e97d036c23bd1775b
First added on: May 08, 2025